<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CCDFD1F9-3405-497D-8CF3-E93B6AB55B1A"><gtr:id>CCDFD1F9-3405-497D-8CF3-E93B6AB55B1A</gtr:id><gtr:name>University of Costa Rica</gtr:name><gtr:address><gtr:line1>Avenida San Pedro y Rotonda de la Bander</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7BF7535A-C8B7-4782-99FF-1191EBA122A0"><gtr:id>7BF7535A-C8B7-4782-99FF-1191EBA122A0</gtr:id><gtr:name>Spanish Ministry of Economy and Competitiveness</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:department>Parasitology</gtr:department><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CCDFD1F9-3405-497D-8CF3-E93B6AB55B1A"><gtr:id>CCDFD1F9-3405-497D-8CF3-E93B6AB55B1A</gtr:id><gtr:name>University of Costa Rica</gtr:name><gtr:address><gtr:line1>Avenida San Pedro y Rotonda de la Bander</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7BF7535A-C8B7-4782-99FF-1191EBA122A0"><gtr:id>7BF7535A-C8B7-4782-99FF-1191EBA122A0</gtr:id><gtr:name>Spanish Ministry of Economy and Competitiveness</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0EF2FC1B-9F48-47DF-B0E6-B442D8B84E98"><gtr:id>0EF2FC1B-9F48-47DF-B0E6-B442D8B84E98</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Casewell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0C9CA68C-EA6D-458F-BEE2-83520D123C9A"><gtr:id>0C9CA68C-EA6D-458F-BEE2-83520D123C9A</gtr:id><gtr:firstName>Juan</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Calvete</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CF1CDBF6-630D-435A-A960-BD2B19C5DC82"><gtr:id>CF1CDBF6-630D-435A-A960-BD2B19C5DC82</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Harrison</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FD84FAD4-8313-4E09-90C4-DA24AF112E0F"><gtr:id>FD84FAD4-8313-4E09-90C4-DA24AF112E0F</gtr:id><gtr:firstName>Jose</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Gutierrez</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FL01839X%2F1"><gtr:id>914C36ED-491E-4D85-B259-EA6DA7CC4630</gtr:id><gtr:title>Novel immuno-proteomic strategies to develop a polyspecific, non-cold chain liquid snake antivenom with unparalleled sub-Saharan African efficacy</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L01839X/1</gtr:grantReference><gtr:abstractText>Snakebite victims in Sub-Saharan Africa are therapeutically neglected (~32,000 deaths; 96,000 disabled yearly) because of the weak efficacy of current polyspecific antivenoms. In areas like Britain with a single venomous snake species, monospecific antivenom (antibodies (abys) purified from the blood of horses/sheep immunised with a single snake venom) are typically highly effective and safe. However, there are several venomous snake groups in sub-Saharan Africa, and polyspecific antivenoms, manufactured with venoms from several snakes, are therefore clinically preferred.

However, using many venoms for immunisation negatively impacts upon the efficacy of polyspecific antivenoms. Thus, the greater the genetic difference between the snakes whose venoms are used in antivenom manufacture, the more numerous and diverse the venom proteins (100+ proteins/venom), and the greater the number of distinct abys generated in the venom-immunised animals. This means that the proportion of total abys targeting the venom of any one snake is small - and consequently more vials of polyspecific antivenom are needed to achieve clinical cure. This significantly increases antivenom-induced adverse effects and often makes treatment unaffordable to the impoverished communities at greatest risk. There is therefore an urgent, compelling need for research to resolve this therapy deficit.

We will use an innovative strategy that greatly expands antivenom snake-species efficacy. Thus, we first add a 'base' antivenom, derived from an existing product that is safe and affordable but exhibits inadequate polyspecific efficacy, onto a laboratory matrix (a chromatography column). We next individually add venoms from all regional medically-important snakes to the column, and all proteins that are not bound by the antivenom are collected and their identity determined. Those found to be pathogenic (many venom proteins are not toxic) are isolated in sufficient amounts for immunisation and mixed with the venoms used to prepare the base antivenom. A new group of sheep is then immunised with the 'venom+supplement toxins' mixture to rationally generate antivenom with greatly expanded snake-species efficacy. 

We will use this approach to first generate new antivenoms to treat either the (i) tissue destruction &amp;amp; bleeding, or the (ii) paralysis pathology syndromes: thereby covering the effects of envenoming by all medically-important sub-Saharan African snakes. We will use a suite of in vitro &amp;amp; in vivo tests to confirm that the two new antivenoms bind the venom proteins causing these pathologies and neutralise their lethal and tissue-destructive effects in mice, and compare these results with that of the base and existing polyspecific antivenoms. With this information as a guide, we will next develop a single pan-African antivenom using the first syndromic antivenom as the base to isolate non-binding proteins from all the African snake venoms for 'venom+supplement' immunisation of a new group of sheep. We will also test the efficacy of an alternate pan-African antivenom created by mixing abys of the two syndromic antivenoms in different ratios, and efficacy-testing the ratio that exhibits maximal binding of proteins from the African snake venoms.

We will also develop/test protocols enabling non-cold chain storage of liquid antivenom - greatly expanding the distribution potential of these improved antivenoms. We will also develop/test protocols to increase the amount and binding strength of antivenom abys to highly toxic venom proteins that are poor at stimulating potent aby responses.

Here, in the only research of its kind, we will deliver new non-cold chain antivenom with pan-African efficacy, and with an unparalleled dose-efficacy ensuring the product poses little adverse-effect risk and is affordable. These antivenoms will represent the most cost-effective investment in snakebite management ever available to governments in sub-Saharan Africa, and elsewhere.</gtr:abstractText><gtr:technicalSummary>To address the sub-Saharan African snakebite therapy deficit, we have devised an innovative 'antivenomic' strategy that maximally exploits the inter- &amp;amp; intra-generic immune cross-reactivity of venom proteins to greatly expand the snake-species efficacy of polyspecific antivenom. 

We first immobilise a 'base' antivenom, derived from an existing antivenom that is safe &amp;amp; affordable but exhibits inadequate polyspecific efficacy, onto an IgG-affinity column, and venoms from target snakes added. All non-binding proteins are collected and proteomically identified. Those found to be toxic (BLAST search of gene/protein databases) are isolated in sufficient amounts for immunisation (preparative scale chromatography) and mixed with the venoms used to prepare the base antivenom. A new group of sheep is then immunised with the 'venom+supplement immunogen' mixture to rationally, and with minimal additional immunogens, generate antivenom with greatly expanded snake-species efficacy. 

We will use this approach to generate antivenoms to treat the (i) dermal necrosis &amp;amp; haemotoxic or the (ii) neurotoxic pathology syndromes: thereby covering the effects of envenoming by all medically-important sub-Saharan African snakes. Thus informed, we will next develop a single pan-African antivenom using the first syndromic antivenom as the base to isolate supplement immunogens from all the African snake venoms for 'venom+supplement' immunisation. We will also develop an alternate pan-African antivenom created by mixing IgGs of both syndromic antivenoms in different ratios, and test the ratio exhibiting maximal polyspecific venom protein binding. Serological and murine venom-neutralising efficacy results of the new antivenoms will be assessed against that of the base and existing polyspecific antivenoms.

We will also develop protocols enabling non-cold chain storage of liquid antivenom, and to increase antivenom IgG titre &amp;amp; avidity to highly toxic venom but weakly immunogenic proteins.</gtr:technicalSummary><gtr:potentialImpactText>OUTPUTS RELEVANT TO BENEFICIARIES 
- Distinct strategies to design polyspecific antivenom with extensive snake-species efficacy.
- The novel toxoiding process to improve immunogenicity of venom toxins. 
- Additives to impart thermostability to liquid biological therapeutics (antisera; vaccines, proteins).
- Snake venom Transcriptomic and Proteomic datasets.

POTENTIAL BENEFICIARIES &amp;amp; HOW THEY WILL BENEFIT 

SNAKEBITE VICTIMS: We designed this pre-clinical project to ultimately save the lives and livelihoods of the medically-neglected snakebite victims of sub-Saharan Africa. 

COMMERCIAL SECTOR: We will deliver the design of non-cold antivenoms with pan-African efficacy and unparalleled dose efficacy and safety - significant, previously missing, incentives to commercial manufacturers. As the antivenoms are delivered during the project, we will pursue translation grants with antivenom manufacturers with a proven record of delivering quality antivenoms to Africa: eg, MicroPharm, Wales; Instituto Clodomiro Picado, Costa Rica. 

The above antivenom manufacturers will gain financially through collaborative translation grants and government contracts and through capacity strengthening. Manufacturers of antivenoms for other regions could also benefit from these incentives. Albeit less certainly, manufacturers of other biological therapeutics may benefit from the thermostability and 'toxoiding' systems developed by this project.

The venom transcriptomic/proteomic data provide an exciting cardiovascular &amp;amp; neurological drug-discovery resource for Biotech/Pharmaceutical industries. We have budgeted for a meeting of relevant individuals from industry and academia to devise a new drug-/reagent-discovery research program.
 
GOVERNMENT POLICY MAKERS: Efficacious and safe antivenoms retailed at affordable prices (relative to existing polyspecific antivenoms) will represent the most cost-effective investment in snakebite management ever available to governments in sub-Saharan Africa - enabling the dislocation of the vicious cycle that has limited the commitment of manufacturers and public health authorities to increase the availability of antivenoms to this region. The health benefits are likely to translate to political advances, both nationally and internationally. 

INTERNATIONAL HEALTH AGENCIES: The current lack of government demand/action and therapeutic tools has limited WHO's ability to motivate other agencies in resolving Africa's snakebite burden. The tools provided here, coupled with renewed manufacturing and government interest is likely to attract the fiscal and health-promoting support of agencies such as DFID, USAID, EU and the Bill and Melinda Gates Foundation - providing them with additional evidence of cost-effective success of using public and philanthropic funds to instigate substantial health benefits in communities whose snakebite victims have been so sorely neglected for so long.
 
PROJECT STAFF AND STUDENTS: The project involves many different scientific disciplines and activities that will enable staff and students from our 3 institutes to improve their technical skills portfolio and subsequent marketability. The project's collaborative nature provides many opportunities for information exchange, science discussion, cultural and scientific environments - all empowerments for young scientists. 

PUBLIC SECTOR: The project's potential to have such a positive impact upon the lives of deeply disadvantaged African populations will have wide appeal to the lay public and media - by demonstrating how UK research funds benefit human health. We will incorporate our progress within our public engagement activities. Furthermore, the collaborative success of three groups from countries from different cultural, economic and geographical backgrounds will strengthen the principle that north-north and north-south international partnerships have great potential for confronting pressing global health issues.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>665597</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Massachusetts (UMass)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Venom immunisation with Glucan particles to improve seroconversion</gtr:description><gtr:id>7B28DA1D-6E9B-4128-8BD4-2F0C38F6AB7C</gtr:id><gtr:impact>none yet</gtr:impact><gtr:partnerContribution>Provision of glucan particles specifically designed (US patent 7,740,861; Ostroff) for delivery of proteins to dendritic cells and other antigen presenting cells.</gtr:partnerContribution><gtr:piContribution>We are trialling a different approach wherein immunisation is conducted with venom encapsulated within glucan particles specifically designed (US patent 7,740,861; Ostroff) for delivery of proteins to dendritic cells and other antigen presenting cells. This is in collaboration with Professor Gary Ostroff, Program in Molecular Medicine and Biochemistry &amp;amp; Molecular Pharmacology, University of Massachusetts Medical School.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Costa Rica</gtr:collaboratingOrganisation><gtr:country>Costa Rica, Republic of</gtr:country><gtr:description>Antivenomics</gtr:description><gtr:id>30977BCA-1FCB-4217-B1EC-89AC6B92383D</gtr:id><gtr:impact>Compiling a database on venom toxicity</gtr:impact><gtr:partnerContribution>Provision of data on the toxicity of venoms from each medically important species of sub-Saharan Africa</gtr:partnerContribution><gtr:piContribution>Provision of venoms from each medically important species od sub-Saharan Africa</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Spanish Ministry of Economy and Competitiveness</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>Spanish National Research Council (CSIC)</gtr:department><gtr:description>Antivenomics</gtr:description><gtr:id>8B2570BC-A595-43CE-8255-D538334919E1</gtr:id><gtr:impact>Compiling database of protein profiles in venoms of each snake of medical importance in sub-Saharan Africa</gtr:impact><gtr:partnerContribution>Provision of proteomic skills and experimental outputs</gtr:partnerContribution><gtr:piContribution>Collaboration on an MRC grant</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Nature News arcticle 2016 by CARRIE ARNOLD</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>322B835E-DE59-4A73-856E-2F6670F66A03</gtr:id><gtr:impact>Nature News articel by Carrie arnold entitled: Synthetic biology tackles antivenom. Artificial antibodies could ease global snakebite burden.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lancet Editorial</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>73FA6513-2484-4963-A241-9DDD6087F690</gtr:id><gtr:impact>Contributed to Lancet Editorial entitled: Snake bite-the neglected tropical disease</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Contributions about the grant objectives to print media</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2A2146C4-4D19-4CDA-9D0A-F733BC122910</gtr:id><gtr:impact>Contributions about the grant objectives to print media</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Snakebite is a disease of the rural poor - MRC research to improve snakebite treatment</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2AB9B39-49B4-4E0E-A1D1-0E2F0627464B</gtr:id><gtr:impact>Several requests for additional information. Acquisition of interest from international health agencies - MSF, Health Action International

More requests for media coverage on this topic</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Canadian medical association Journal news piece - Snakebite neglect rampant in Africa</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>215E1688-D6D0-46D1-9C8A-0AAEB888E98E</gtr:id><gtr:impact>Contributed to Canadian medical association Journal news piece entitled: Snakebite neglect rampant in Africa</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Collaboration with Liverpool Museum on Ssssnakes Aliver Exhibition</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>73D8B251-24EF-4DE5-8F2A-224C79413C04</gtr:id><gtr:impact>200,000 museum visitors attended the exhibition - that included the message: snakebite is a disease of the rural poor in Africa and Asia

Local newspaper, TV coverage. Numerous comments from parents of young children who visited the exhibition</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Filming for Reuters News agency</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F2BC454D-66A1-4359-9885-1B05B1154226</gtr:id><gtr:impact>Promotion of the project objectives</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.reuters.com/video/2015/04/02/deadly-snakes-milked-to-create-potent-ne?videoId=363714832</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Filming for BBC website</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3CA6906A-D8CE-43A7-A61A-974739F089B3</gtr:id><gtr:impact>Promotion of the objectives of the grant</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/science-environment-30727879</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nature News</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4825CA62-199D-4139-9DB5-2E462433C14A</gtr:id><gtr:impact>Nature News article by QUIRIN SCHIERMEIER entitled: Africa braced for snakebite crisis
Health specialists warn that stocks of antivenom will run out in 2016.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lillian Lincoln Documentary Film</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D5CF6C5A-7301-4435-AE09-169C2F224F5D</gtr:id><gtr:impact>Lillian Lincoln Documentary Film - contributed to film content and structure, provided Kenyan location and contacts for filming, was filmed in Uk and Kenya</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nature News arcticle by CARRIE ARNOLD</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4F8FCA39-40A9-483B-BF2E-16287B608A8E</gtr:id><gtr:impact>Contributed to Nature News article - The snakebite fight
Snakes kill tens of thousands of people each year. But experts can't agree
on how best to overcome a desperate shortage of antivenom.
BY CARRIE ARNOLD</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Filming for the BBC News Global Health</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C25A0C99-23A1-4191-A009-22BA4BA6CC4B</gtr:id><gtr:impact>promotion of the MRC award and its objectives</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/health-34176581</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sir Halley Stewart Trust</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Sir Halley Stewart Trust</gtr:fundingOrg><gtr:fundingRef>146</gtr:fundingRef><gtr:id>1C34429B-346B-42D2-AE49-B0E4E2A7F402</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO Guidelines for the Production Control and Regulation of snake antivenom immunoglobulins</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>FC0A8F28-1404-4A32-ACAA-C0F7FDF9D8C1</gtr:id><gtr:impact>The results of the NC3R project has led to inclusion of several 3R recommendations that have been incorporated into the updated (2017) WHO Guidelines for the Production Control and Regulation of snake antivenom immunoglobulins.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Software to compile, annotate NGS sequence data into a venom gland transcriptome</gtr:description><gtr:id>BB3B305C-5B20-4378-841E-D59D8C836169</gtr:id><gtr:impact>This program has been requested by several individuals</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>VT builder</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Compilation of venom proteomes for each species of medically0important snake in Sub-Saharan Africa</gtr:description><gtr:id>7A8D90BB-39C3-43C9-BDAB-918DE1DCC813</gtr:id><gtr:impact>Still under contruction</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>venom proteomics</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>The most comprehensive collection of snake venom-induced pathology for sub-Saharan Africa</gtr:description><gtr:id>400FE6A9-3F7B-40B2-BE27-770D143B840A</gtr:id><gtr:impact>This is the most comprehensive collection of snake venom-induced pathology for sub-Saharan Africa</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Venom pathology profiling</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Compilation of venom gland transcriptomes for each species of medically important snake in subSaharan Africa</gtr:description><gtr:id>95FBAAA3-3B45-42C2-8452-25DDD6701AF2</gtr:id><gtr:impact>Still under contruction</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Venom transcriptomes</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Collection of snakes and snake venoms</gtr:description><gtr:id>32C98C82-F090-49CA-A7A4-A80FCD8E3407</gtr:id><gtr:impact>This is the critical resource enabling progress in downstream research objectives</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Collection of snakes and snake venoms</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>VTBuilder: a tool for the assembly of multi isoform transcriptomes. BMC Bioinformatics 15, 389.</gtr:description><gtr:id>ABA86B0B-C005-4310-8200-0F58901B0712</gtr:id><gtr:impact>Use of this bioinformatic tool by other groups</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>VTBuilder</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F276BCDB-1DD9-41E0-B823-7BA5EEFE5CFE"><gtr:id>F276BCDB-1DD9-41E0-B823-7BA5EEFE5CFE</gtr:id><gtr:title>Priority Actions and Progress to Substantially and Sustainably Reduce the Mortality, Morbidity and Socioeconomic Burden of Tropical Snakebite.</gtr:title><gtr:parentPublicationTitle>Toxins</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c0ef0c524da8f116b91162fb765d35ba"><gtr:id>c0ef0c524da8f116b91162fb765d35ba</gtr:id><gtr:otherNames>Harrison RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2072-6651</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/66AFB6E0-A03F-49D2-8AE1-226324281706"><gtr:id>66AFB6E0-A03F-49D2-8AE1-226324281706</gtr:id><gtr:title>Anti-angiogenic activities of snake venom CRISP isolated from Echis carinatus sochureki.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5c940e619e60d966a2ca7b526c97f12c"><gtr:id>5c940e619e60d966a2ca7b526c97f12c</gtr:id><gtr:otherNames>Lecht S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0C735697-C638-4C1D-A6B7-2CD11FF0C9BD"><gtr:id>0C735697-C638-4C1D-A6B7-2CD11FF0C9BD</gtr:id><gtr:title>A Call for Incorporating Social Research in the Global Struggle against Snakebite.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8f03003ee5e9d27475d11a31d3be2d77"><gtr:id>8f03003ee5e9d27475d11a31d3be2d77</gtr:id><gtr:otherNames>Guti?rrez JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EAFA81D3-2A7F-4AF0-9B0B-188D911B7EB9"><gtr:id>EAFA81D3-2A7F-4AF0-9B0B-188D911B7EB9</gtr:id><gtr:title>Visual Pigments, Ocular Filters and the Evolution of Snake Vision.</gtr:title><gtr:parentPublicationTitle>Molecular biology and evolution</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b30dfc3a1925c296b668bfa39b1a358c"><gtr:id>b30dfc3a1925c296b668bfa39b1a358c</gtr:id><gtr:otherNames>Sim?es BF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0737-4038</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D6395731-7BAB-4D56-8E8E-463321BB7262"><gtr:id>D6395731-7BAB-4D56-8E8E-463321BB7262</gtr:id><gtr:title>Stabilising the Integrity of Snake Venom mRNA Stored under Tropical Field Conditions Expands Research Horizons.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/89272bb61e943f9567e7039df470d9f1"><gtr:id>89272bb61e943f9567e7039df470d9f1</gtr:id><gtr:otherNames>Whiteley G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/13A921F5-D36A-4AD0-9B62-CBC15C3ABBF1"><gtr:id>13A921F5-D36A-4AD0-9B62-CBC15C3ABBF1</gtr:id><gtr:title>What killed Karl Patterson Schmidt? Combined venom gland transcriptomic, venomic and antivenomic analysis of the South African green tree snake (the boomslang), Dispholidus typus.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1649ec990e5a627bce787e80697585fb"><gtr:id>1649ec990e5a627bce787e80697585fb</gtr:id><gtr:otherNames>Pla D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7F2A9D8B-22FE-4359-AF5A-8A7C48D47296"><gtr:id>7F2A9D8B-22FE-4359-AF5A-8A7C48D47296</gtr:id><gtr:title>A multicomponent strategy to improve the availability of antivenom for treating snakebite envenoming.</gtr:title><gtr:parentPublicationTitle>Bulletin of the World Health Organization</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8f03003ee5e9d27475d11a31d3be2d77"><gtr:id>8f03003ee5e9d27475d11a31d3be2d77</gtr:id><gtr:otherNames>Guti?rrez JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0042-9686</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5B1FA3AC-DA6F-41E9-B860-DF3B77AA2B07"><gtr:id>5B1FA3AC-DA6F-41E9-B860-DF3B77AA2B07</gtr:id><gtr:title>Top-down venomics of the East African green mamba, Dendroaspis angusticeps, and the black mamba, Dendroaspis polylepis, highlight the complexity of their toxin arsenals.</gtr:title><gtr:parentPublicationTitle>Journal of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b5b56d5ae9ced9cfae47a69aee9c8e1a"><gtr:id>b5b56d5ae9ced9cfae47a69aee9c8e1a</gtr:id><gtr:otherNames>Petras D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1874-3919</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L01839X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>6393C0B5-F394-4AB6-9626-AD6D94C7BCB5</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Injuries and Accidents</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>